Leerink Partnrs Has Pessimistic View of Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Leerink Partnrs cut their Q2 2025 earnings per share (EPS) estimates for Hologic in a report released on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will earn $1.02 per share for the quarter, down from their prior forecast of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic’s Q2 2026 earnings at $1.15 EPS, Q3 2026 earnings at $1.18 EPS, Q4 2026 earnings at $1.19 EPS and FY2026 earnings at $4.65 EPS.

Other equities analysts have also issued research reports about the stock. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Jefferies Financial Group assumed coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $88.92.

Hologic Stock Up 0.9 %

Shares of NASDAQ HOLX opened at $70.37 on Wednesday. The stock has a market capitalization of $15.88 billion, a P/E ratio of 21.13, a PEG ratio of 2.38 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. Hologic has a one year low of $68.61 and a one year high of $84.67. The firm’s 50 day simple moving average is $74.46 and its two-hundred day simple moving average is $78.36.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.89 EPS.

Hedge Funds Weigh In On Hologic

A number of institutional investors have recently added to or reduced their stakes in HOLX. Wolff Wiese Magana LLC bought a new stake in shares of Hologic in the 3rd quarter worth approximately $25,000. General Partner Inc. purchased a new position in Hologic during the fourth quarter valued at $26,000. Groupama Asset Managment boosted its holdings in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares in the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic in the second quarter worth $37,000. Finally, First Horizon Advisors Inc. grew its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.